Milestone Pharmaceuticals, Inc.
(NASDAQ : MIST)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.21%177.130.7%$1337.46m
MRKMerck & Co., Inc. -0.33%90.870.7%$1163.98m
PFEPfizer Inc. -1.35%51.730.9%$1098.82m
LLYEli Lilly & Co. -1.33%319.941.1%$1031.84m
BMYBristol-Myers Squibb Co. -1.21%76.071.0%$995.69m
ABBVAbbVie, Inc. -0.61%152.221.9%$952.84m
AZNAstraZeneca Plc -1.26%65.241.0%$435.93m
SGENSeagen Inc. 1.35%179.335.7%$320.16m
TPTXTurning Point Therapeutics, Inc. -0.11%75.170.0%$287.77m
GSKGSK Plc -0.38%43.360.2%$275.37m
NVSNovartis AG -1.04%83.650.2%$162.86m
HZNPHorizon Therapeutics Plc 0.51%80.175.4%$162.64m
MRTXMirati Therapeutics, Inc. 5.37%70.741.6%$154.60m
ALNYAlnylam Pharmaceuticals, Inc. 1.71%148.358.1%$142.92m
NVONovo Nordisk A/S -0.77%110.570.1%$142.12m

Company Profile

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.